149 related articles for article (PubMed ID: 11689583)
1. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
[TBL] [Abstract][Full Text] [Related]
3. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Clive S; Gardiner J; Leonard RC
Cancer Chemother Pharmacol; 1999; 44 Suppl():S29-30. PubMed ID: 10602908
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Smorenburg CH; Seynaeve C; Bontenbal M; Planting AS; Sindermann H; Verweij J
Anticancer Drugs; 2000 Nov; 11(10):825-8. PubMed ID: 11142690
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
6. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine: new preparation. Solution for cutaneous application.
Prescrire Int; 1998 Feb; 7(33):5-6. PubMed ID: 10183390
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
[TBL] [Abstract][Full Text] [Related]
9. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
[TBL] [Abstract][Full Text] [Related]
10. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
Hartmann K; Siebenhaar F; Belloni B; Brockow K; Eben R; Hartmann B; Ruëff F; Schoepke N; Staubach P; Weber A; Maurer M
Br J Dermatol; 2010 Jan; 162(1):185-90. PubMed ID: 19785605
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine in recurrent cutaneous breast cancer.
Clive S; Leonard RC
Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
[No Abstract] [Full Text] [Related]
12. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
[No Abstract] [Full Text] [Related]
13. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
Eilender D; LoRusso P; Thomas L; McCormick C; Rodgers AH; Hooper CL; Tornyos K; Krementz ET; Parker S; Morgan LR
Cancer Chemother Pharmacol; 2006 Jun; 57(6):719-26. PubMed ID: 16184382
[TBL] [Abstract][Full Text] [Related]
14. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Sindermann H; Peukert M; Hilgard P; Engel J; Eibl H
Prog Exp Tumor Res; 1992; 34():153-9. PubMed ID: 1438798
[No Abstract] [Full Text] [Related]
15. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
17. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
18. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
19. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
[TBL] [Abstract][Full Text] [Related]
20. [Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Viseux V; Schoenlaub P; Danhier S; Vilque JP; Plantin P
Ann Dermatol Venereol; 2004 Feb; 131(2):204-5. PubMed ID: 15026752
[No Abstract] [Full Text] [Related]
[Next] [New Search]
